Navigation Links
Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
Date:10/21/2008

TSX Exchange Symbol: RVX

CALGARY, Oct. 21 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that the ongoing double blind placebo controlled Phase 1b/2a study in subjects with normal and low HDL is progressing as planned. The subjects in the first group receiving a low dose of RVX-208 show safety and tolerability. Thus the safety committee the has made a decision to commence the next cohort in which 24 subjects will receive treatment doses escalating each week, for a total of 4 weeks.

Donald J. McCaffrey, President and CEO of Resverlogix stated, "We are very pleased to be able to share this exciting clinical information with the Clinical Advisory Board at the American Heart Association meeting on November 8th."

Resverlogix will give an oral presentation during the American Heart Association Scientific Sessions meeting in November 2008 where the Company will present novel data for RVX-208 to attendees. Due to the nature of double blinded clinical trials and strict embargo rules set by the American Heart Association, data from this Phase 1b/2a clinical trial will not be presented in full until the completion of the trial.

About RVX-208

RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-I production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport (RCT).

RCT is a pathway by which accumulated cholesterol is transported from the arterial wall to the liver for excretion, thus preventing atherosclerosis. Major constituents of RCT include acceptors such as high-density lipoprotein (HDL) and apolipoprotein A-I (ApoA-I). A critical part of RCT is cholesterol efflux, in which accumulated cholesterol is removed from macrophages.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Resverlogix Announces Closing of Debt Redemption
2. Resverlogix Eliminates Sixty Percent of Remaining Debt
3. Resverlogix Issues a Management Statement
4. Resverlogix Board of Directors Update
5. Resverlogix Notice of Conference Call & Webcast
6. Jan Gray Joins Resverlogix Board of Directors
7. Resverlogixs Lead Drug Featured in Key Scientific Publication
8. Industry Leaders Select Resverlogixs RVX-208
9. /C O R R E C T I O N from Source -- Resverlogix Corp./
10. Resverlogix Notice of Conference Call & Webcast
11. Resverlogix Share Option Extension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... focused on quality, regulatory and technical consulting, provides a free webinar ... presented on July 13, 2016 at 12pm CT at no charge. , Incomplete ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... partnership that will allow them to produce up ... (HiPSC) from one lot within one week. These ... their time laboriously preparing cells and spend more ... made possible through a proprietary, high-volume manufacturing process ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):